Navigation Links
Ovarian Cancer Prognosis May Depend on Gene Mutations
Date:4/4/2011

MONDAY, April 4 (HealthDay News) -- Ovarian cancer patients with the BRCA2 gene mutation are more likely to survive than those with the BRCA1 mutation or patients without either mutation, a new study finds.

U.S. researchers analyzed 3,531 cases of epithelial ovarian cancer, including 1,178 patients with BRCA1 mutations, 367 with BRCA2 mutations and 1,986 with neither mutation.

Five-year survival rates were 61 percent for those with the BRCA2 mutation, 46 percent for those with the BRCA1 mutation and 36 percent for those with neither mutation, the investigators found.

The study is to be presented Monday at the annual meeting of the American Association for Cancer Research, in Orlando, Fla. The research is considered preliminary until it is published in a peer-reviewed journal.

"There was some previous evidence that women with ovarian cancer who have mutations in the BRCA genes show improved survival compared to non-mutation carriers. Our study clearly shows that this survival difference is real. We also provide the first solid evidence that BRCA1 and BRCA2 mutations don't have the same impact on ovarian cancer survival," Kelly Bolton, a fellow at the U.S. National Cancer Institute, said in an AACR news release.

Further research is needed to find out why BRCA2 mutations are associated with better survival than BRCA1 mutations or no mutations. The mutations may affect a patient's response to chemotherapy, Bolton suggested.

About 1 in 400 to 1 in 800 women are born with either the BRCA1 or BRCA2 mutations, which increase the risk of ovarian and breast cancer. About 5 percent of ovarian cancer patients have BRCA1 or BRCA2 mutations.

More information

The American Cancer Society has more about ovarian cancer.

-- Robert Preidt

SOURCE: American Association for Cancer Research, news release, April 4, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Philanthropic pledge triples funds for TGen ovarian cancer research
2. Ohio State study: Targeted ovarian cancer therapy not cost-effective
3. GPs take more than a month to record ovarian cancer diagnosis in one in 10 cases
4. Nearly 25% of Women With Early Ovarian Cancer Not Given Recommended Biopsies
5. New clinical trial to determine ovarian cancer risks in African-American women
6. Ovarian Cyst Syndrome May Raise Health Risks from Plastics Chemical
7. UH biochemist works to revolutionize ovarian cancer treatment
8. Ovarian cancer advances when genes are silenced
9. Few Lives Saved by Ovarian Cancer Screening: Study
10. Biological diversity of ovarian cancer lessens value of screening
11. Researchers map the way to personalised treatment for ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Ovarian Cancer Prognosis May Depend on Gene Mutations
(Date:2/6/2016)... ... 2016 , ... Research has shown that building shame resilience ... and level of relapse. , At the 2016 iaedp Symposium, the ... the critical tasks of the recovery phase and beyond including relapse prevention and ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the ... a variety of colors, assortments and packaging. This staple for Valentine’s Day is a ... location. , For Valentine’s Day, not only are long-stem roses available, but also ...
(Date:2/5/2016)... City, UT (PRWEB) , ... February 05, 2016 , ... ... Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi Foster, specialist in ... Humans Amateur TV Network. , Each week, on his weekly Whole-Food Warrior TV show, ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its fiscal year and fourth quarter ... --> GAAP results: Revenue for the fourth quarter ... 4.1% from the third quarter of 2015, and up ... 2014. Revenue for the year ended December 31, 2015 was ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology: